Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Vertex Presents Phase II Data

Vertex Pharmaceuticals Inc. (VRTX - Free Report) recently announced final data from a phase II study of VX-809 and Kalydeco. The phase II study evaluated adults suffering from cystic fibrosis (CF) and two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del.

The study evaluated patients with increasing doses of VX-809 alone for the first 28 days. The next 28 days evaluated the effect of the combination of VX-809 and Kalydeco. The data revealed that patients receiving the combination of VX-809 and Kalydeco showed a significant improvement in lung function compared to placebo from day 28 to 56.

The positive data from the phase II study will encourage Vertex’s plans to begin a pivotal study evaluating the combination of VX-809 (600mg) and Kalydeco (250mg) in homozygous subjects in early 2013.

Very recently, Vertex had announced positive data on Kalydeco from a long-term follow-up study, PERSIST, that was conducted in patients suffering from CF. Vertex plans to initiate three additional pivotal studies this year to evaluate the safety and efficacy of Kalydeco.

A life threatening genetic disease, CF as estimated by Vertex, afflicts approximately 70,000 people worldwide.

We remind investors that Kalydeco was approved in the US, in February 2012, for treating CF patients 6 years and above. Vertex recorded sales of $18.4 million for Kalydeco in the first quarter of 2012.

Vertex is set to gain approval of the drug for the same indication in the European Union (EU), with the European Committee for Medicinal Products for Human Use having given a positive opinion recently.

Our Take

We note that Kalydeco had a strong first quarter and, with the probable EU launch, the drug can be a major growth driver in the future. We expect investor focus to remain on Kalydeco’s EU approval and its performance in the US.

We currently have a Neutral recommendation on Vertex Pharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Resources

Client Support

Follow Us

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Copyright 2017 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25% per year. These returns cover a period from 1988-2016 and were examined and attested by Baker Tilly Virchow Krause, LLP, an independent accounting firm. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zack Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.